Safety considerations for an Rx to OTC Switch Program

Duration: 51 minutes


Webinar Recording

If you do not wish to receive any communication from us, you may unsubscribe at any time. Click here to view our privacy policy.


Why watch

Key Learnings

  •  Understand how safety considerations affect the many aspects of an Rx-to-OTC switch program
  •  Integrate FDA’s principal safety concerns into a switch submission
  •  Understand how analyses are conducted to support a product’s safety  
  •  Examine how these elements apply in a case study
speakers

A full day of inspirational speakers

Proud to bring inspirational speakers from across the globe. 



Bao-Anh Nguyen-Khoa

Senior Manager, Pharmacovigilance, Epidemiology & Risk Management (PER-EPI), PharmaLex US Corporation

Bao is a licensed clinical pharmacist with Doctor of Pharmacy (with a residency in Drug Information) and Master of Public Health degrees. He joined PharmaLex (via The Degge Group, Ltd.) in 2003 and is currently a Senior Research Manager with the pharmacoepidemiology and drug safety group (PER-EPI).